Chargement en cours...
Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
Mesalamine (5-ASA) is the mainstay therapy in patients with mild-to-moderate active ulcerative colitis (UC). However, non-adherence to therapy and practice variability among gastroenterologists represent long-standing barriers, leading to poor outcomes. Additionally, targets to treat in UC are incre...
Enregistré dans:
| Publié dans: | J Clin Med |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
MDPI
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7564568/ https://ncbi.nlm.nih.gov/pubmed/32911840 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9092905 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|